Compare MSGM & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGM | COCP |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 15.3M |
| IPO Year | 2020 | 2011 |
| Metric | MSGM | COCP |
|---|---|---|
| Price | $4.88 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 80.6K | 33.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.02 |
| EPS | ★ 1.32 | N/A |
| Revenue | $741,000.00 | ★ $12,712,091.00 |
| Revenue This Year | $69.07 | N/A |
| Revenue Next Year | $30.56 | N/A |
| P/E Ratio | $3.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.86 |
| 52 Week High | $5.41 | $2.19 |
| Indicator | MSGM | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 75.73 | 50.02 |
| Support Level | $2.87 | $1.01 |
| Resistance Level | $5.41 | $1.11 |
| Average True Range (ATR) | 0.32 | 0.06 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 97.77 | 44.50 |
Motorsport Games Inc is a motorsport network company that combines engaging video games with esports competitions and content for racing fans and gamers around the globe. The company has its reportable segments into the development and publishing of interactive racing video games, entertainment content and services, and the organization and facilitation of esports tournaments, competitions, and events for licensed racing games as well as on behalf of third-party video game racing series and other video game publishers. The majority of the revenue is earned from Gaming.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).